Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall

The company’s midstage clinical trial had positive results, and the condition in question affects an estimated 100 million people in the U.S.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.